Drug resistance: An overview of the current state of the art

International Journal of Oncology

Volumn 9, Issue 2, 1996, Pages 197-203

  Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

DNA repair; Drug resistance; LRP; MDR; MRP; P glycoprotein; Platinum complexes; Topoisomerase I; Topoisomerase II

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; ACLARUBICIN; AMONAFIDE; ANTINEOPLASTIC AGENT; AZATOXIN; DACTINOMYCIN; DAUNORUBICIN; DISTAMYCIN A; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FOSTRIECIN; INTOPLICINE; MERBARONE; MITOXANTRONE; PLATINUM COMPLEX; QUINOLONE DERIVATIVE; SAINTOPIN; SURAMIN; TENIPOSIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER RESISTANCE; DNA REPAIR; DNA SUPERCOILING; DRUG TRANSPORT; ENZYME MODIFICATION; GENE EXPRESSION REGULATION; HUMAN; MULTIDRUG RESISTANCE; ONCOGENE C MYB; PRIORITY JOURNAL; REVIEW;

EID: 0030038297     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Kessel D, Botterill V and Wodinsky I: Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res 28: 938-941, 1968.
2. Biedler J and Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 30: 1174-1184, 1970.
3. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466-483, 1973.
4. Ling V and Thompson L: Reduced permeability of CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103-116, 1974.
5. Bradley G and Ling V: P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223-233, 1994.
6. Childs S and Ling V: The MDR superfamily of genes and its biological implications. In: Important Advances in Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). JB Lippincott, Philadelphia, pp21-36, 1994.
7. Ruetz S and Gros P: A mechanism for P-glycoprotein action in multidrug resistance: are we there yet? Trends Pharmacol Sci 15: 260-263, 1994.
8. Hill BT: Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro. Cytotechnology 12: 265-288, 1993.
9. McClean S and Hill BT: Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug resistance phenotype in Chinese hamster ovary cells. Eur J Cancer 29: 2243-2248, 1993.
10. Bradley G, Naik M and Ling V: P-glycoprotein expression in multidrug resistant human ovarian carcinoma cell lines. Cancer Res 49: 2790-2796, 1989.
11. Whelan RDH, Waring CJ, Wolf CR, Hayes JD, Hosking LK, and Hill BT: Overexpression of P-glycoprotein and glutathione S-transferase π in MCF-7 cells selected for vincristine resistance in vitro. Int J Cancer 52: 241-246, 1992.
12. Skovsgaard T, Nielsen D, Maare C and Wassermann K: Cellular resistance to cancer chemotherapy. Int Rev Cytol 156: 77-157, 1994.
13. Hu XF, Slater A, Wall DM, Kantharidis P, Parkin JD, Cowman A and Zalcberg JR: Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71: 931-936, 1995.
14. Yang X and Page M: P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res 7: 619-624, 1995.
15. Muller C, Goubin F, Ferrandis E, Cornil-Scharwtz I, Bailly JD, Border C, Benard J, Sikic BI and Laurent G: Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol Pharmacol 47: 51-56, 1995.
16. Childs S, Yeh RL, Georges E and Ling V: Identification of a sister gene to P-glycoprotein. Cancer Res 55: 2029-2034, 1995.
17. Pinedo HM and Giaccone G: P-glycoprotein: A marker of cancer-cell behaviour. New Engl J Med 21: 1417-1419, 1995.
18. Cole SPC and Deeley RG: Multidrug resistance associated with overexpression of MRP. Adv Cancer Res (In press).
19. Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochemical Sci 17: 463-468, 1992.
20. Muller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, de Vries EGE and Jansen PLM: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033-13037, 1994.
21. Hosking LK, Whelan RDH, Shellard SA, Davies SL, Hickson ID, Danks MK and Hill BT: Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. Int J Cancer 57: 259-267, 1994.
22. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. New Engl J Med 334: 231-238, 1996.
23. Kruh GD, Gaughan KT, Godwin A and Chan A: Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 87: 1256-1258, 1995.
24. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J and Broxterman HJ: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68: 939-946, 1993.
25. Gollapudi S, Thadepalli F, Kim CH and Gupta S: Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Oncol Res 7: 213-225, 1995.
26. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC and Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nature Med 1: 578-582, 1995.
27. Slovak ML, Ho JP, Cole SPC, Deeley RG, Greenberger L, de Vries EGE, Broxterman HJ, Scheffer GL and Scheper RJ: The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55: 4214-4219, 1995.
28. Rome L, Kedersha N and Chugani D: Unlocking vaults: organelles in search of a function. Trends Cell Biol 1: 47-50, 1991.
29. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG: Pharmacological characterization of mutlidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
30. r 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 55: 102-110, 1995.
31. Izquierdo MA, van der Zee A, Vermorken J, van der Valk P, Belien J, Giaccone G, Scheffer GL, Flens Mj, Kennemans J, Pinedo HM, Meijer CJLM, de Vries EGE and Scheper RJ: The drug resistance-associated marker LRP predicts poor response to platinum-alkylating chemotherapy and outcome in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995.
32. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJLM, van der Valk P and Scheper RJ: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148: 877-888, 1996.
33. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC and Sehested M: Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.
34. Schuurhuis GJ, Broxtenman HJ, Ossenkoppele GJ, Baab JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pieters R, Lankelma J and Pinedo HM: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1: 81-93, 1995.
35. Beck WT, Danks MK, Wolverton JS, Kim R and Chen M: Drug resistance associated with altered DNA topoisomerase II. Advan Enzyme Regul 33: 113-127, 1993.
36. Hofmann GA and Mattern MR: Topoisomerase II in multiple drug resistance. Cytotechnology 12: 137-154, 1993.
37. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530-542, 1994.
38. r 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 55: 2129-2134, 1995.
39. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM and Holguin MH: Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707-1716, 1995.
40. Gupta M, Fujimori A and Pommier Y: Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1262: 1-14, 1995.
41. Kaufmann SH, Charron M, Burke PJ, Karp JE: Changes in topoisomerase II levels and localization during myeloid maturation in vitro and in vivo. Cancer Res 55: 1255-1260, 1995.
42. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T: DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303, 1995.
43. Berger JM, Gamlin SJ, Harrison SC and Wang JC: Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232, 1996.
44. Lelievre S, Benchokroun Y and Kragh Larsen A: Suramin-resistant fibrosarcoma cells show altered DNA topoisomerase I and II activities with novel features. Proc Am Assoc Cancer Res 36: 450, 1995;
45. published subsequently - Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Mol Pharmacol 47: 898-906, 1995.
46. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278, 1992.
47. Eng W-K, Faucette L, Johnson RK and Sternglanz R: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755-760, 1988.
48. Nitiss JL, Liu Y-X, Harbury P, Jannatipur M, Wasserman R and Wang JC: Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52: 4467-4472, 1992.
49. Leteurtre F, Fujimore A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G, Nakano H and Pommier Y: Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem 269: 28702-29707, 1994.
50. De Vries EGE, Muller M, Meijer C, Jansen PLM and Mulder NH: Role of the glutathione S-conjugate pump in cisplatin resistance. J Natl Cancer Inst 87: 537, 1995.
51. Barret J-M, Calsou P, Larsen AK, Salles B: Cisplatin resistance in a murine leukemia cell line is partly dependent upon topoisomerase II activity. Mol Pharmacol 46: 431-436, 1995.
52. Lepre CA and Lippard SJ: Interaction of platinum antitumor compounds with DNA. Nucleic Acids Mol Biol 4: 9-38, 1990.
53. Calsou P, Barret J-M, Cros S and Salles B: DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur J Biochem 211: 403-409, 1993.
54. Ploy ACM, Van Dijk M, Berends F and Lohman PHM: The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. Cancer Res 45: 4178-4184, 1985.
55. Hill BT, Scanlon KJ, Hanson J, Harstrick A, Pera M, Fichtinger-Schepman AMJ and Shellard SA: Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30A: 832-837, 1994.
56. Shellard SA, Hosking LK and Hill BT: Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line. Biochem Pharmacol 47: 775-779, 1994.
57. Hill BT, Shellard SA, Fichtinger-Schepman AMJ, Schmoll HJ and Harstrick A: Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anti-Cancer Drug 5: 321-328, 1994.
58. Zhen W, Link CJ, O'Connor PM, Reed E, Parker R, Howell SB and Bohr VA: Increased gene-specific repair of cisplatin interstrand adducts in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698, 1992.
59. Chu G: Cellular responses to cisplatin - The roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790, 1994.
60. Taverna P, Hansson J, Scanlon KJ, Hill BT: Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 15: 2053-2056, 1994.
61. Weeda G, van Ham RCA, Vermeulen W, Bootsma D, van der Eb AJ and Hoeijmakers JHJ: A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome. Cell 62: 777-791, 1990.